Ikarian Capital, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Ikarian Capital, LLC
- $606 Million
- Q4 2024
A detailed history of Ikarian Capital, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 349,649 shares of CPRX stock, worth $7.73 Million. This represents 1.2% of its overall portfolio holdings.
Number of Shares
349,649
Previous 417,850
16.32%
Holding current value
$7.73 Million
Previous $8.31 Million
12.15%
% of portfolio
1.2%
Previous 1.45%
Shares
4 transactions
Others Institutions Holding CPRX
# of Institutions
348Shares Held
98.5MCall Options Held
13.4KPut Options Held
11.7K-
Black Rock Inc. New York, NY18.7MShares$413 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$186 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$128 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$69.2 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$66.6 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.27B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...